In order to examine the regulation of Ral in vivo we have used an affinity precipitation assay for activated Ral. This assay is based on the ability of GTPase effector proteins to interact specifically with the activated, GTP-bound form of the GTPase; this type of assay has been used previously to assay levels of Ras-GTP [12, 13] . We can detect Ral-GTP in cell lysates by precipitation with a glutathione-S-transferase (GST) fusion protein containing the Ral-binding domain of RIP1 [8] . The validity of this assay was tested by transient transfection assays in COS-7 cells (Figure 1a) . Cotransfection of RalGDS with RalB substantially increased the amount of precipitated Ral-GTP. As expected, an activated mutant of RalB (RalB Q72L ) was precipitated in significantly greater quantities than wild-type RalB, and expression of a dominant-negative RalB mutant (RalB S28N ) resulted in precipitation of very little Ral-GTP (Figure 1a) , even in the presence of RalGDS. Overexpression of an activated Ras mutant (Ras G12V ), however, had very little effect on the activation of RalB (Figure 1b) , and a RalGDS mutant (RalGDS∆RID) lacking the Ras-interacting domain was able to activate RalB (Figure 1b) . These results suggest that Ral can be activated by RalGDS, not only by Ras-dependent mechanisms, but also by Ras-independent pathways.
Results and discussion
In order to examine the regulation of Ral in vivo we have used an affinity precipitation assay for activated Ral. This assay is based on the ability of GTPase effector proteins to interact specifically with the activated, GTP-bound form of the GTPase; this type of assay has been used previously to assay levels of Ras-GTP [12, 13] . We can detect Ral-GTP in cell lysates by precipitation with a glutathione-S-transferase (GST) fusion protein containing the Ral-binding domain of RIP1 [8] . The validity of this assay was tested by transient transfection assays in COS-7 cells (Figure 1a ). Cotransfection of RalGDS with RalB substantially increased the amount of precipitated Ral-GTP. As expected, an activated mutant of RalB (RalB Q72L ) was precipitated in significantly greater quantities than wild-type RalB, and expression of a dominant-negative RalB mutant (RalB S28N ) resulted in precipitation of very little Ral-GTP (Figure 1a) , even in the presence of RalGDS. Overexpression of an activated Ras mutant (Ras G12V ), however, had very little effect on the activation of RalB (Figure 1b) , and a RalGDS mutant (RalGDS∆RID) lacking the Ras-interacting domain was able to activate RalB (Figure 1b) . These results suggest that Ral can be activated by RalGDS, not only by Ras-dependent mechanisms, but also by Ras-independent pathways.
To further characterize the role of Ras in Ral activation we examined the effect of mitogens on the activation of endogenous Ral protein in Rat-2 fibroblasts. When cells were serum-starved for 24 hours and then stimulated with fetal calf serum (FCS), Ral was rapidly activated; Ral activation reached a maximum after 2 minutes and returned close to the pre-stimulation level within 30 minutes (Figure 2a) . Stimulation of quiescent Rat-2 cells with either LPA or EGF also led to rapid activation of Ral (Figure 2a ) with similar kinetics to those observed with FCS. Both LPA and EGF have been shown to lead to activation of Ras in fibroblasts [14, 15] . To determine if Ral activation is Ras-dependent, we examined the effects of LPA and EGF on a Rat-2 cell line that expresses Ras S17N under the control of the metal-inducible metallothionein promoter (R2-N17 cells) [16] . The activation state of Ras was measured by precipitating Ras-GTP with a GST fusion protein containing the Ras-binding domain of c-Raf1 [17] . Ras was strongly activated by LPA or EGF in control Rat-2 cells, but Ras activation could not be detected in the R2-N17 cells, even when Ras S17N was not induced (Figure 2b and data not shown), indicating that small amounts of Ras S17N are sufficient to inhibit Ras activation. We have shown previously that the expression of Ras S17N also blocked the induction of Erk2 mitogen-activated protein (MAP) kinase activity in these cells [16] . In contrast, both LPA and EGF stimulated Ral activation in the presence of significant amounts of Ras S17N (Figure 2b ), demonstrating that EGF and LPA can induce Ral activation in the absence of a detectable increase in Ras-GTP.
To determine if active Ras is sufficient to activate endogenous Ral, we used a Rat-2 cell line that expresses activated Ras Q61L under the control of a tetracycline-repressible promoter. Cells were serum starved for 24 hours in the presence of tetracycline, then washed and further incubated in serum-free medium without tetracycline to induce Ras Q61L expression. The cells were lysed at intervals and Ral activation was measured (Figure 2c ). Ral was reproducibly activated 8 hours after withdrawal of tetracycline at times when there was only a modest increase in Ras expression. Activation of Ral did not increase at later times, even though expression of Ras Q61L continued to increase. The amount of Ral-GTP returned to background levels 12 hours after induction, and cells that had been without tetracycline for 24 hours and expressed significant amounts of Ras Q61L contained very little Ral-GTP (Figure 2c ). These results indicate that Ras activation is sufficient to activate Ral, although the level of Ral-GTP following induction of Ras Q61L was considerably less than that observed with LPA or EGF, and FCS could activate Ral in cells in which Ras Q61L was no longer effective (Figure 2c ). Taken together with the failure of Ras S17N to block Ral activation by these mitogens, these findings suggest that Ral activation can be mediated by Ras-independent signaling pathways.
LPA has been shown to stimulate several intracellular signaling pathways via distinct G-protein-coupled receptors. LPA stimulates Ras-GTP accumulation (and inhibits adenylyl cyclase) through the pertussis-toxin-sensitive G i protein, activates PLC via G q protein and also signals to the small GTPase Rho through the G 12/13 protein [11] . EGF activates Ras through the well-characterized Grb2-Sos pathway [18] and also stimulates PLC activity in some cell types [19] . PLC in turn generates two second messengers: inositol 1,4,5-trisphosphate, which releases Ca 2+ from internal stores leading to an increase in intracellular Ca 2+ , and diacylglycerol, which is an activator of protein kinase C [10] . To determine the possible role of these second messengers in Ral activation, we used the Ca 2+ ionophore ionomycin to elevate the concentration of intracellular Ca 2+ , and the phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA) to activate protein kinase C [20] . Whereas treatment of quiescent Rat-2 cells with ionomycin activated Ral, no effect was seen for TPA (Figure 3a ), indicating that an increase in intracellular Ca 2+ is sufficient to activate Ral.
To determine whether PLC activation can account for the effects of LPA and EGF on Ral activation, we examined the effect of U-73122, an inhibitor of agonist-induced PLC activity [21] , on Ral-GTP accumulation triggered by these mitogens. When serum-starved Rat-2 cells were exposed to LPA or EGF in the presence or absence of U-73122, the mitogen-induced increase in Ral-GTP was completely blocked in cells that had been pre-treated with the PLC inhibitor (Figure 3b ), indicating that PLC activity is necessary for Ral activation by these mitogens. In contrast, when cells were treated with pertussis toxin to inhibit LPAinduced activation of Ras [15] , accumulation of Ral-GTP stimulated by LPA was only minimally affected ( Figure 3b ). As expected, the PLC inhibitor had little effect on Ral-GTP levels induced by ionomycin (Figure 3b ).
In summary, our results represent a direct demonstration that Ral can be activated through multiple signaling pathways. Our data confirm previous findings that Ral can be activated by a Ras-dependent signaling pathway [2, 3, 5] ; a recent report indicates that in NIH3T3 cells Ral activation by mitogens is Ras-dependent [22] . We extend these 840 Current Biology, Vol 8 No 14
Figure 1
The activation of Ral in transfected COS-7 cells. (a) COS-7 cells were transfected with 300 ng RalB, 300 ng RalB plus 50 ng RalGDS, 300 ng RalB S28N plus 150 ng RalGDS, or 300 ng RalB Q72L DNA as indicated, and grown in medium supplemented with 10% FCS before lysis. Ral-GTP was precipitated with glutathione-Sepharose-bound GST-RIP and both the pellet (upper panel) and supernatant fractions (lower panel) were analyzed by immunoblotting with the indicated antibodies. One representative experiment is shown. (b) COS-7 cells were transfected with 300 ng RalB, 50 ng RalGDS, 50 ng RalGDS∆RID and 50 ng Ha-Ras G12V constructs as indicated and grown in medium containing serum. Ral-GTP was precipitated as in (a) and both the pellet and supernatant fractions were analyzed by immunoblotting. The graph shows data from five independent experiments (results are mean values ± SD) and the western blots are from one representative experiment. The effect of mitogens and mutant forms of Ras on the activation of endogenous Ral. (a) Mitogen-induced activation of Ral in serumstarved Rat-2 cells. Cells were stimulated with 10% FCS, 100 ng/ml EGF or 5 µg/ml LPA, and Ral-GTP levels were analyzed at the indicated times as described for Figure 1 . The graph shows data from two experiments (mean ± SD) and the western blots are from one representative experiment. (b) Effect of dominant-negative Ras on mitogen-induced Ral activation. Parental Rat-2 cells or those expressing Ras S17N under the control of the metallothionein promoter (R2-N17) were serum-starved for 24 h. Ras S17N expression was induced in one set of R2-N17 cells by adding ZnCl 2 and CdCl 2 to a final concentration of 20 µM and 0.4 µM, respectively; the other set were not induced (NI). Cells were then treated with 100 ng/ml EGF, 5 µg/ml LPA or buffer alone (control) for 2 min. Ral-GTP and Ras-GTP were precipitated with GST-RIP or the Raf GST fusion protein, respectively, and analyzed by SDS-PAGE and immunoblotting. The graph shows data from two experiments in cells stimulated with LPA or EGF (mean ± SD) and the western blots are from one representative experiment in cells stimulated with LPA. (c) Rat-2 cells expressing the activated Ras Q61L mutant under control of a tetracycline-repressible promoter (R2tTA-Q61L) were serumstarved for 24 h in the presence of tetracycline, washed twice with PBS and incubated in serum-free medium without tetracycline to induce Ras Q61L expression. Cells were lysed at the indicated times after the removal of tetracycline and Ral-GTP was assayed. The FCS stimulation at 24 h was for 2 min at 10%. The graph shows data from three experiments (mean ± SD) and the western blots are from one representative experiment.
Figure 3
The role of Ca 2+ in the activation of endogenous Ral. (a) The effect of ionomycin and TPA on the activation of Ral in serumstarved Rat-2 cells. Cells were stimulated with 0.5 µg/ml ionomycin (iono) or 100 ng/ml TPA, and Ral-GTP was assayed at the indicated times. The graph shows data from two experiments (mean ± SD) and the western blots are from one representative experiment. (b) The effect of the PLC inhibitor U-73122 or pertussis toxin (PTX) on Ral activation. Rat-2 cells were serum-starved for 24 h and then incubated with U-73122 (10 µM) for 5 min, with pertussis toxin (1 µg/ml) for 2 h or with DMSO for 5 min (no inhibitor). Cells were stimulated with 5 µg/ml LPA, 100 ng/ml EGF, 0.5 µg/ml ionomycin or vehicle alone (C). Endogenous Ral-GTP and Ras-GTP levels were assayed as described in the legends to Figures 1 and 2 . The graph shows data from three experiments (mean ± SD) and the western blots are from one representative experiment. No inhibitor PTX U-73122
While this paper was under review, Wolthuis et al. [23] reported that activation of Ral in platelets is Ca 2+ -dependent and does not correlate with Ras activation. Mechanisms that might mediate the effect of Ca 2+ on Ral activation include the phosphorylation of RalGDS by the multifunctional Ca 2+ -calmodulin-dependent kinase II (CaMK-II) or the direct interaction of Ca 2+ -calmodulin with Ral [24] . Thus, Ral represents a potential site for integration of Ras-dependent and Ras-independent signaling pathways.
Materials and methods

Cell culture and transfections
All cell lines were cultured in F10/DME (2:1) supplemented with 10% (volume : volume) FCS. COS-7 cells (1 × 10 6 cells per 6 cm dish) were transiently transfected using the Lipofectamine reagent (GIBCO) according to the recommendations of the manufacturer. Rat-2 cells were seeded into 10 cm dishes at 50% confluency and grown overnight in standard medium (10% FCS). Cells were then serum starved for 24 h in F10/DME containing 20 mM Hepes buffer pH 7.4 (Hepes was used to minimize pH fluctuations during the subsequent mitogen treatment). Cells were stimulated at room temperature by adding mitogens from concentrated stocks directly to the medium; control unstimulated cells received an equal volume of the appropriate vehicle (10 mM acetic acid containing 1 mg/ml bovine serum albumin (BSA) for EGF; PBS containing 1 mg/ml BSA for LPA; and DMSO for ionomycin and TPA). The cells were incubated at room temperature for a maximum of 3 min, and, when longer stimulation times were required, the cells were returned to the incubator until lysis.
Ral-GTP and Ras-GTP precipitation assays
After transfection or mitogen treatment, cells were washed twice in icecold PBS and lysed in 0.5 ml (COS-7 cells) or 1 ml (Rat-2 cells) ice-cold lysis buffer (50 mM Tris.HCl pH 7.5, containing 150 mM NaCl, 20 mM MgCl 2 , 1% NP-40 and protease inhibitors). Samples were adjusted to the same protein concentration in a final volume of 0.5 ml or 1 ml. GST fusion proteins (6 µg of GST-RIP or 10 µg of the Raf GST fusion protein) adsorbed to glutathione-Sepharose beads were added and incubated for 2 h at 4°C with mixing. Samples of the supernatants (1/10) were removed and the beads were washed three times in lysis buffer. Pellet and supernatant samples were subjected to electrophoresis on 7.5-15% step-gradient SDS-polyacrylamide gels and blotted onto the same sheet of Immobilon transfer membrane (Millipore). Ral proteins were detected by immunoblotting with monoclonal antibody RB9, which recognizes both RalA and RalB, followed by incubation with an HRPconjugated secondary antibody to mouse immunoglobulin (Pierce 
Materials and methods
Construction of plasmids
Mammalian expression plasmids were constructed as follows. The coding sequence of rat RalGDSb [S1] was subcloned as a BamHI-SalI fragment into a modified Bluescript vector to attach a Kozak consensus sequence 5′ to the initiation codon. The RalGDS∆RID mutant which lacks the entire Ras-interacting domain was generated by isolating a BamHI-PstI fragment containing the first 765 codons and ligating it into the modified vector; an in-frame stop codon was created by cleavage of the DNA with EcoRI, blunting with Klenow DNA polymerase and digestion with NotI, generating a fragment that was then ligated into pBluescript that had been cleaved with BamHI, blunted with Klenow polymerase and digested with NotI. Using the polymerase chain reaction (PCR) the coding sequence of RalB was amplified from pET5c-RalB (obtained from R. Weinberg) with a 5′ oligonucleotide encoding a Kozak recognition site and the fragment was subcloned into pBluescript. The Ral mutants Ral S28N and Ral Q72L were constructed using the PCR [S2] . All constructs were verified by dideoxy sequencing and/or restriction digest and subsequently inserted as NotI-SalI fragments into the expression plasmid pMT3 [3] . A plasmid that expresses activated Ras, pDCR-Ras G12V [S3] , was obtained from M. White. To express the Ras Q61L mutant under control of a tetracycline-repressible promoter, the coding sequence of Ras Q61L was excised from pZIP-RasH(Q61) [S4] by digestion with BamHI and inserted into pUHG10-3 [S5] (obtained from M. Gossen), to generate pUHG-ras Q61L . Plasmids encoding GST fusion proteins were constructed as follows: pGEX-RalB was generated by subcloning the RalB coding sequence as a BamHI-SalI fragment into pGEX-KG [S6]. To obtain pGEX-RalGDS(658C) a SacI fragment containing the final 238 codons of RalGDSb was subcloned into pGEX-KG. A SacI fragment containing the Ral-binding domain of RIP1 was isolated from pEXlox-RIP1 [8] and inserted into pGEX-KG to generate pGEX-RIP. The GST-GNH construct, which contains the Ras-binding domain of c-Raf1 has been described [17] .
Generation of cell lines
The R2-N17 cell line which expresses the dominant-negative Ras S17N mutant under the control of the metal-inducible metallothionein promoter has been described [16] . We used the system described by Gossen and Bujard [S5] to generate a Rat-2 cell line which expresses activated Ras Q61L under the control of a tetracycline-repressible promotor. Rat-2 cells were transfected with pUHD15-1neo (encoding the transactivator protein) by electroporation and clones were selected in medium containing G418. Several clones were screened by transient transfection with a luciferase reporter (pUHC13-3) and one clone was expanded into the cell-line R2tTA. To generate the R2tTA-Q61L cell line, R2tTA cells were co-transfected by electroporation with pUHGras Q61L and a plasmid encoding a puromycin-resistance marker.
Protein purification and monoclonal antibodies
GST fusion proteins were expressed in Escherichia coli. Cells were suspended in phosphate buffered saline (PBS; 140 mM NaCl, 2.7 mM KCl, 10 mM Na 2 HPO 4 , 1.8 mM KH 2 PO 4 , pH 7.4) containing a protease inhibitor cocktail and lysed by sonication. Insoluble material was removed by centrifugation at 10,000 × g. Triton X-100 was added to 1% (volume : volume) and proteins were purified by adsorption to glutathione-Sepharose beads. The resin was washed by three cycles of centrifugation at 1000 × g and re-suspension in PBS. The protein content was estimated by SDS-PAGE followed by Coomassie staining using BSA as standard. For generation of monoclonal antibodies, soluble antigen was obtained by cleaving GST-RalB and GST-RalGDS(658C) with thrombin (0.1% weight : weight) and removing the resin by centrifugation. Balb/c mice were immunized with purified proteins in Ribi adjuvant (RIBI ImmunoChem). Splenocytes were fused to Ag653B myeloma cells and antigen-specific hybridomas were established according to standard protocols.
